SAN DIEGO, Oct. 14 -- aTyr Pharma announced today that Dr. Floyd Bloom Professor Emeritus, Molecular and Integrative
According to Jeff Watson, Ph. D. and CEO of aTyr Pharma, “Developing a new class of biologics with applications in a number of therapeutic areas such as inflammation, cardiovascular, hematology, neurology and metabolism requires deep knowledge in particular disease areas. Dr. Bloom is the consummate scientist in the field of neurobiology, and has shown ability to translate that knowledge into human therapies by his founding and role as CEO at Neurome. We are thrilled to be able to apply his knowledge and expertise to our understanding of resectin biology.”
Professor Paul Schimmel, co-founder of aTyr Pharma, fellow National Academy member and Professor at the Scripps Research Institute added, “I have known, respected and admired Dr. Bloom’s integrity and scientific excellence for decades. Dr. Bloom’s unparalleled expertise brings additional scientific authority to what was already a world class scientific advisory board at aTyr Pharma. Dr. Bloom’s influence and guidance, will help us accelerate our understanding and development of aTyr Pharma’s novel class of therapeutic proteins.”
About Dr. Bloom
After receiving an A. B., cum laude, from Southern Methodist University, Dr. Bloom went on to receive his M. D. cum laude from the Washington university School of Medicine before completing a residency and internship at the Barnes-Jewish Hospital. His scientific career has led to a number of key leadership positions such as Director of Behavioral Neurobiology at the Salk Institute for Biological Studies, Chief of the Laboratory of Neuropharmacology at the National Institute of Mental Health, Chair Emeritus of the Department of Neuropharmacology at The Scripps Research Institute. Awards and recognition of his scientific skills and contributions to society include 6 honorary doctorates, the Pasarow Award in Neuropsychiatry, the Hermann van Helmholz Award, the Sarnat Award for Mental Health Research and his election to prestigious societies such as the National Academy of Sciences, the Institute of Medicine, the American Philosophical Society and the Royal Swedish Academy of Science. Demonstrating a broad commitment to the advancement of science, Dr. Bloom has been the editor-in-chief of Science, arguably one of the highest impact scientific journals in the world, and has also served as President of the American Association for the Advancement of Science. One of the most influential scientists in the world, Dr. Bloom has authored or co-authored over 400 research articles, 29 monographs, over 250 solicited reviews and articles, over 50 editorials and over 300 abstracts.
About aTyr Pharma
aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery of an entirely new class of biologics. aTyr Pharma’s discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These proteins are being developed as novel therapeutics to treat cancer, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.
SOURCE aTyr Pharma, Inc.
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All